Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia

van Spronsen, Francjan J.; Himmelreich, Nastassja; Rufenacht, Veronique; Shen, Nan; van Vliet, Daniëlle; Al-Owain, Mohammed; Ramzan, Khushnooda; Alkhalifi, Salwa M.; Lunsing, Roelineke J.; Heiner-Fokkema, Rebecca M.

Published in:
JOURNAL OF MEDICAL GENETICS

DOI:
10.1136/jmedgenet-2017-104875

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
SHORT REPORT

Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: from attention deficit to severe dystonia and intellectual disability


ABSTRACT

Background Autosomal recessive mutations in DNAJC12, encoding a cochaperone of HSP70 with a hitherto unknown function, were recently described to lead to hyperphenylalaninemia, central monoamine neurotransmitter (dopamine and serotonin) deficiency, dystonia and intellectual disability in six subjects affected by homozygous variants.

Objective Patients exhibiting hyperphenylalaninemia in whom deficiencies in hepatic phenylalanine hydroxylase and tetrahydrobiopterin cofactor metabolism had been excluded were subsequently analysed for DNAJC12 variants.

Methods To analyse DNAJC12, genomic DNA from peripheral blood (Sanger sequencing), as well as quantitative messenger RNA (Real Time Quantitative Polymerase Chain Reaction (RT-qPCR)) and protein expression (Western blot) from primary skin fibroblasts were performed.

Results We describe five additional patients from three unrelated families with homozygosity/compound heterozygosity of DNAJC12 with three novel variants: c.85delC/p.Gln29Lysfs*38, c.596G>C/p.*199Leuext*42 and c.214C>T/p.(Arg72*). In contrast to previously reported DNAJC12-deficient patients, all five cases showed a very mild neurological phenotype. In two subjects, cerebrospinal fluid and primary skin fibroblasts were analysed showing similarly low 5-hydroxyindolacetic acid and homovanillic acid concentrations but more reduced expressions of mRNA and DNAJC12 compared with previously described patients. All patients responded to tetrahydrobiopterin challenge by lowering blood phenylalanine levels.

Conclusions DNAJC12 deficiency appears to result in a more heterogeneous neurological phenotype than originally described. While early identification and institution of treatment with tetrahydrobiopterin and neurotransmitter precursors is crucial to ensure optimal neurological outcome in DNAJC12-deficient patients with a severe phenotype, optimal treatment for patients with a milder phenotype remains to be defined.

INTRODUCTION

Today, many countries have adopted newborn screening for phenylketonuria (PKU; phenylalanine hydroxylase (PAH) deficiency, OMIM 261600), which is based on high phenylalanine (Phe) concentrations in dried blood spots (DBSs). Immediate institution of treatment can effectively reduce plasma Phe concentrations and prevent classical PKU symptomatology. About 1%–2% of all cases identified with HPA in newborn screening are due to disorders affecting BH4 metabolism. While patients with classical PKU present with very high blood Phe concentrations, BH4 deficiencies present with dopamine and serotonin deficiencies besides HPA (for a broader view of BH4 in enzyme function see). Central dopamine and serotonin deficiencies are reflected by low homovanillic acid (HVA) and 5-hydroxyindolacetic acid (5HIAA) in cerebrospinal fluid (CSF), respectively. Accordingly, treatment consists of BH4 to normalise plasma Phe concentrations as well as with L-dopa/carbidopa and 5-hydroxytryptophan precursors to reduce neurological symptoms caused by the dopamine and serotonin deficiencies.

Recently, autosomal recessive deficiency of DNAJC12, which is thought to act as a cochaperone for PAH, tyrosine hydroxylase and tryptophan hydroxylase, has been described as a cause for HPA. Similar to disorders of BH4 metabolism (and classical PKU), DNAJC12 variants cause dopamine and serotonin deficiency in addition to HPA. Clinically, the six consanguineous patients with homozygous DNAJC12 mutant alleles who have been reported thus far showed intellectual disability and severe neurological symptoms including dystonia. Herein, we present five additional patients with HPA without PAH mutations or any known defect in BH4 metabolism, who turned out to have biallelic DNAJC12 deficiency. The two siblings of Caucasian background (Dutch) with compound heterozygous DNAJC12 variants and the three children of Saudi origin with a homozygous genotype described here all showed a very mild neurological phenotype.

METHODS

Subjects

All clinical data were obtained with written informed consent from the parents of all investigated subjects, in agreement with the Declaration
Biochemical genetics

of Helsinki and approved by the Ethical Committees of the centres participating in this study, where biological samples were obtained.

Family 1

**Patient 1-A** is a boy and was born at term after an uneventful pregnancy from non-consanguineous parents with a Caucasian pedigree (Dutch). He was identified with HPA at day 5 by newborn screening (NBS) with a blood Phe concentration of 500 μmol/L. The neonatal BH₄ loading test (20 mg/kg) showed a reduction in plasma Phe concentrations from 330 to 120 μmol/L after 8 hours, suggesting BH₄ deficiency. However, a BH₄ defect was ruled out by a normal urinary pterin profile and normal dihydropteridine reductase (DHPR) activity in DBS. He was therefore considered to have mild PAH deficiency, although genotyping did not show any mutations in the PAH. A Phe-restricted diet kept plasma Phe concentrations <360 μmol/L. Development in infancy was normal. From the age of 2.5 years, he showed behavioural issues of hyperactivity and attention deficit. At age 6 years, neuropsychological assessment showed a disharmonic intelligence profile (Wechsler Intelligence Scale for Children- III (WISC-III); full scale IQ 108; verbal 125; performance 88) and attention deficit hyperactivity disorder (ADHD) (inattention type) with a differential diagnosis of Asperger’s. In 2009, a 48-hour BH₄-loading test (20 mg/kg) was performed, which reduced plasma concentrations from 350 to 95 μmol/L. He was subsequently treated with BH₄ (11–13 mg/kg/day), which allowed him to have an unrestricted diet (plasma Phe concentrations ranging between 49 and 475 μmol/L). Neuropsychological assessment at 10 and 13 years of age showed a normal IQ and executive functions but minor problems in facial recognition and the identification of facial emotions, thinking problems and both social and internalising problems. Neurological examination at 13 years of age showed a low passive tone, but normal active tone, subtle signs of dystonia when walking (on toes) and suboptimal alternating hand movements with the non-dominant hand. CSF analysis (at the age of 13 years) revealed normal pterins but low biogenic amines (SHIAA and HVA; see table 1). Due to the fact that that the CSF results rather than the clinical symptoms clearly support central dopamine deficiency, it was considered unnecessary to start L-dopa/carbidopa treatment.

Patient 1-B is a girl (sister of patient 1A) and was born after an uneventful pregnancy and delivery and was diagnosed with HPA following a blood Phe concentration of 433 μmol/L on the second day after birth. Given the history of her brother, pterin and DHPR analyses were not performed, and a Phe-restricted diet was immediately initiated. Early development was slow but within the normal limits. From the age of 4 years, it was noted at school that she had difficulty interacting with other children. Neuropsychological assessment showed indications for autism spectrum disorder, but this was not further investigated. At the age of 5 years, a 48-hour BH₄-loading test (20 mg/kg) showed a reduction in plasma Phe concentrations from 346 to 109 μmol/L, and she was treated with BH₄ (15–20 mg/kg/day), which allowed her to have an unrestricted diet (plasma Phe concentrations largely <360 μmol/L). Neuropsychological assessment at 8 and 11 years of age showed a normal IQ and executive functions, and only minor problems in facial recognition and the identification of facial emotions as well as increased social problems. Neurological examination performed at the age of 11 years showed a low passive tone and suboptimal alternating hand movements with the non-dominant hand. CSF analysis (at the age of 11 years) revealed normal pterins but low biogenic amines (SHIAA and HVA; see table 1). Due to the fact that that the CSF results rather than the clinical symptoms clearly support central dopamine deficiency, it was considered unnecessary to start L-dopa/carbidopa treatment.

More information on the subjects and on materials and methods are described in the online supplementary materials and methods.

**RESULTS**

We report on five patients with HPA from three unrelated families in whom neither PAH variants nor any known defect in BH₄ metabolism was identified, that is, pterin analysis and DHPR enzyme activity were in the normal range and no mutations were identified, who turned out to have biallelic DNAJC12 deficiency. A summary of genetic and biochemical data as well as clinical characteristics and current treatment of our patients is summarised in table 1. For comparison, the biochemical and clinical characteristics from the first six previously described DNAJC12-deficient patients are also listed. Blood Phe levels in our DNAJC12-deficient patients were between 420 and 526 μmol/L, similar to previously described subjects. They all responded to an oral challenge with BH₄ (20 mg/kg) by lowering their blood Phe concentrations to almost normal. In two patients from family 1, CSF investigations revealed low concentrations of SHIAA and HVA, comparable with previously published patients. Nevertheless, in all our patients, the clinical phenotype was much milder than described previously. Apparently, neither blood Phe levels nor CSF neurotransmitter metabolites are a good predictor of the severity of neurological disease in DNAJC12-deficient patients. In the two siblings from non-consanguineous parents (family 1), a compound heterozygous genotype with two novel DNAJC12 variants (c.85delC/p.Gln299Lysfs*38 and c.596G>T/p.*199Leuext*42) was identified. The other three patients from consanguineous parents (families 2 and 3) were all homozygous for another novel DNAJC12 variant c.214C>T (p.Arg72*). In summary, the three novel variations include one frameshift mutation, a non-sense mutation and a 42-nucleotides extension due to the stop codon mutation. While the frameshift and the non-sense mutations are predicted to be deleterious or disease causing, the effect of the stop codon mutation may be less obvious. Theoretically, the stop-codon variant results in a slightly longer protein with an extra tag on the C-terminus. However, it is believed that quality surveillance mechanisms protect the cell from such potentially harmful mutant proteins by mRNA elimination and/or protein degradation. Degradation of such a DNAJC12 mutant is corroborated by the analysis of fibroblasts from patients 1-A and 1-B, where both the DNAJC12 transcript (mRNA) and protein expression in fibroblasts were markedly reduced as compared with healthy controls (figure 1A and B).

The variants are deposited in the locus-specific database PNDdb at http://www.biopku.org.

**DISCUSSION**

We report on five individuals in three families in whom HPA is caused by the recently identified DNAJC12 deficiency. In contrast to the previously reported six DNAJC12-deficient patients, who all presented with severe neurological symptoms if not treated early with a combination of BH₄ and neurotransmitter precursors L-DOPA/carbidopa and 5-hydroxytryptophan, the here presented patients show only mild neurological symptoms, behavioural problems and/or mild hypotonia, if any symptoms at all. The patients of family 1, in succession, have...
Table 1  Overview of genetic, biochemical and clinical characteristic of subjects identified thus far with DNAJC12 deficiency

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1-A</th>
<th>1-B</th>
<th>2-A</th>
<th>2-B</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA variation</td>
<td>c.[85delC];[596G&gt;T]</td>
<td>c.[85delC];[596G&gt;T]</td>
<td>c.[214C&gt;T];[214C&gt;T]</td>
<td>c.[214C&gt;T];[214C&gt;T]</td>
<td>c.[214C&gt;T];[214C&gt;T]</td>
</tr>
<tr>
<td>Location in exon #</td>
<td>E2;E5</td>
<td>E2;E5</td>
<td>E3;E3</td>
<td>E3;E3</td>
<td>E3;E3</td>
</tr>
<tr>
<td>Protein alteration</td>
<td>p.[Gln29Lysfs<em>38];[199Leuext</em>42]</td>
<td>p.[Gln29Lysfs<em>38];[199Leuext</em>42]</td>
<td>p.[Arg72*];[Arg72*]</td>
<td>p.[Arg72*];[Arg72*]</td>
<td>p.[Arg72*];[Arg72*]</td>
</tr>
<tr>
<td>Age (at diagnosis)</td>
<td>13 years</td>
<td>11 years</td>
<td>25 months</td>
<td>3 years</td>
<td>10 years</td>
</tr>
<tr>
<td>First blood Phe (μM)</td>
<td>500</td>
<td>433</td>
<td>526</td>
<td>509</td>
<td>420</td>
</tr>
<tr>
<td>BH4 loading test</td>
<td>Responsive</td>
<td>Responsive</td>
<td>Responsive</td>
<td>Responsive</td>
<td>Responsive</td>
</tr>
<tr>
<td>SHIAA (nmol/L)</td>
<td>28 (↓)</td>
<td>20.3 (↓)</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>(ref.range: 74–163)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HVA (nmol/L)</td>
<td>108 (↓)</td>
<td>86 (↓)</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>(ref.range: 33–551)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neopterin (nmol/L)</td>
<td>14.5 (n)</td>
<td>11.3 (n)</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>(ref.range: 3–20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopterin (nmol/L)</td>
<td>19.1 (n)</td>
<td>15.0 (n)</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>(ref.range: 10–30)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dystonia + (subtle)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/6</td>
</tr>
<tr>
<td>Speech delay</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2/6</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/6</td>
</tr>
<tr>
<td>Axial hypotonia + (mild)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Limb hypertonia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Nystagmus</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Oculogyric crisis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Attention difficulties</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6</td>
</tr>
<tr>
<td>Current treatment</td>
<td>Yes (BH)</td>
<td>Yes (BH)</td>
<td>None</td>
<td>None</td>
<td>Yes (BH, plus NT)</td>
</tr>
</tbody>
</table>

*unclear, ↓, reduced; n, normal; ↑, elevated; SHIAA, 5-hydroxyindolacetic acid; CSF, cerebrospinal fluid; HVA, homovanillic acid; n.d., not done; NT, neurotransmitter precursors; Phe, phenylalanine.
Moreover, our studies in primary skin fibroblasts from these patients show a reduced expression of both mRNA and DNAJC12 than with one of the previously described patients with a more severe phenotype. Therefore, a potential reverse relation between DNAJC12 expression and severity of phenotype needs further functional studies and investigations.

The very recently published key statements of the first European PKU guidelines state that in every child who is referred for HPA, both pterins and DHFR activity should be assessed to exclude disorders of BH₄ metabolism. Non-classical HPA (BH₄ deficiencies) is a rather rare group of disorders with overall prevalence of 1:500,000 newborns, and it is probably too early to estimate prevalence of DNAJC12 deficiency. Together with the previously reported DNAJC12-deficient patients, the here described cases show that, besides disorders of BH₄ metabolism, DNAJC12 deficiency should also be included in the differential diagnosis of HPA. This is especially warranted if a (neonatal) BH₄-loading test is performed and normalises plasma Phe concentrations, while disorders of BH₄ metabolism have been ruled out, and genetic testing for PAH deficiency has not revealed any variant. The previously reported cases showed that early identification and prompt institution with BH₄ and neurotransmitter precursors is crucial to prevent intellectual disability and severe neurological symptoms including movement disorders such as dystonia. The here presented cases, having a much milder neurological phenotype, raise the question whether such treatment should be initiated in all DNAJC12-deficient patients to optimise neurological outcome. Investigations of biogenic amines in CSF are essential for such decisions.

In view of the defective DNAJC12 itself, it is known that the DNAJC heat shock protein family (HSP40) member C12 undergoes interdependences. In view of the defective DNAJC12 itself, it is known that the DNAJC heat shock protein family (HSP40) member C12 undergoes interdependences. To conclude, we report on five additional cases with HPA due to DNAJC12 deficiency in whom neurological symptoms are much milder than in the six patients who have been previously reported. Thereby, DNAJC12 variants seem to cause a heterogeneous neurological phenotype, of which the severity is not reflected by plasma Phe nor CSF neurotransmitter metabolite levels. While early identification and institution of treatment with BH₄ and neurotransmitter precursors is crucial to ensure optimal neurological outcome in DNAJC12 deficiency patients with a severe phenotype, optimal treatment for patients with a milder phenotype remains to be defined.

**Author affiliations**

1. Beatrix Children’s Hospital, University Medical Center, University of Groningen, Groningen, The Netherlands.
2. Dietmar-Hopp Metabolic Center, University Children’s Hospital, Heidelberg, Germany.
3. Division of Metabolism, University Children’s Hospital Zurich, Zurich, Switzerland.
4. Department of Rehabilitation Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

---

**Figure 1** DNAJC12 expression in patient’s fibroblasts. (A) DNAJC12 (mRNA) expression in patient’s fibroblasts in relation to reference Rab7 gene expression (n=3). Besides control fibroblasts, the DNAJC12 deficient patient with the homozygous DNAJC12 variations c.[215G>C];[215G>C]/p.(Arg72Pro)[Arg72Pro] previously published by Anikster et al as patient C-II-4, ¹ and patients 1-A and 1-B from the here described family 1 are shown. Relative mRNA expression revealed a significant but variable reduction of around 0.5 (±0.25) in patient C-II-4. The here described Dutch siblings, that is, patient 1-A and patient 1-B (family 1) with the compound heterozygous variations c.[85delC];[596G>T];p.[Gln29Lysfs*389];[*199Leuext*42] resulted in a more significant reduction of mRNA expression levels of around 0.23 (±0.09) and 0.25 (±0.08) compared with control, respectively. (B and C) Corresponding DNAJC12 protein expression in patient’s fibroblasts. Western Blot analysis (100 µg total protein) of DNAJC12 in patients’ fibroblasts detected no significant difference between control and patient C-II-4, similarly to what was reported before, but strongly diminished protein levels in patients 1-A and 1-B (family 1) compared with control fibroblasts (normalised against β-actin). Values after protein normalisation (in C): control 100±14.9%, C-II-4 97.5±12.1%, patient 1-A 49.4±5.3%, patient 1-B 20.6±4.5%.

---

been treated with a Phe-restricted diet and with BH₄ monotherapy without substitution of neurotransmitter precursors. Most of the time, patients in family 2 have received no treatment at all, while the patient in family 3 is doing well on moderate dosages of BH₄, L-DOPA/carbidopa and 5-hydroxytryptophan. Despite the very mild clinical phenotype, however, CSF neurotransmitter metabolite concentrations in the two patients from family 1 were remarkably similar low as the previously reported in DNAJC12-deficient patients. Patients described in this study are, however, slightly younger (family 2) than those previously described and the patient from family 3 was already on treatment for several years at the time of molecular diagnosis, which may have affected the natural course of the disease. One may speculate that a long-term exposure to elevated blood and brain Phe levels (inhibition of other large-neutral amino acids at the blood–brain barrier), together with impaired CNS synthesis of biogenic amines (competitive inhibition of tyrosine and tryptophan hydroxylases) could result in a more severe neurological presentation, including intellectual disability and Parkinsonism. Moreover, our studies in primary skin fibroblasts from these same two patients with the milder phenotype exhibited a more reduced expression of both mRNA and DNAJC12 than with one of the previously described patients with a more severe phenotype.
Department of Medical Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Department of Pediatrics, Maternity and Children Hospital, Dammam, Saudi Arabia
Department of Pediatric Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Department of Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Zurich, Switzerland
Children's Research Centre (CRC), University Children's Hospital Zürich, Zurich, Switzerland
The Neuroscience Center Zurich (ZNZ), The Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland

Acknowledgements
The authors would like to thank the families for participating and supporting this study.

Contributors
FVs, NB and BT contributed equally in writing and preparing of the manuscript, including table 1. NH and NS assisted in developing figures and description of methods. FVs, DvV, MA-O, KR, SMA, RIL and RMH-F provided patients' data and performed clinical assessments. NS, VR, NH, AR and CG-B performed biochemical, metabolic and genetic analyses. FVs, GHF, NB and BT supervised the study.

Funding
This work is part of the RD-CONNECT initiative and was supported by the FP7-HEALTH-2012-INNOVATION-1 EU Grant No. 305444 (to NB) and funding from the Dietmar-Hopp Foundation (to GHF and NB).

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
Declaration of Helsinki and approved by the Ethical Committees of the centres participating in this study.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
Additional unpublished data.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES